Over the last couple of decades, the growth in knowledge of the pharmacokinetics and pharmacodynamics of intravenous anaesthetic agents has resulted in a better understanding of the relationship between drug dose, blood concentration, biophase concentration and effect. With the combined advancement of computer technology and the production of simulation programmes and target-controlled infusion devices, total intravenous anaesthesia (TIVA) has enjoyed a surge in popularity.
The popularity of TIVA
In an unpublished national survey, our Anaesthetic Department forwarded questionnaires to every trust in the country in order to establish the popularity and perceived advantages and disadvantages of TIVA. Of 241 questionnaires, 79 were returned, giving a response rate of 33%. The total number of consultants in these trusts was 1172 and 397 (34%) of these used a TIVA technique at least once a month. Consultants who used TIVA were asked what they considered to be the advantages and disadvantages of the technique. The perceived advantages are shown in Table 1 and will be of no surprise to those who use the technique. Table 2 shows the perceived disadvantages.
Pharmacokinetic modelling
Target-controlled infusion (TCI) and its associated pharmacokinetic programmes have been developed to attain, maintain or alter the plasma concentration of intravenous anaesthetic agents. Because these systems control the plasma concentration, the clinical effects reflecting the effect-site concentration are often delayed. The delay in equilibration of the blood and effectsite concentrations causes hysteresis.
For propofol, the best pharmacokinetic parameter sets are associated with a low bias and acceptable precision. The parameters have led to the development of the Diprifusor which is a TCI system controlling predicted plasma concentration of propofol. It controls the rate of propofol delivered to achieve and maintain the calculated target blood propofol concentration, and enables the anaesthetist to titrate this concentration against patient requirements. If, however, the TCI system calculates or controls the effect-site concentration, the delay of transfer across the blood brain barrier and equilibration is taken into account, enabling the anaesthetist to have better control of drug action. The above concepts involve many assumptions and pharmacokinetic modelling, especially as effect-site concentration cannot be measured. This is an area with scope for further investigation and development. Propofol is well established and commonly used by TCI, but future systems may involve other intravenous hypnotic agents, analgesics and muscle relaxants.
Drugs
The effect of opioids on the pharmacokinetics and pharmacodynamics of propofol Propofol, when given as a sole agent via a TCI pump, has been shown to achieve higher measured blood concentration than that predicted, with the difference increasing as the target propofol concentration increases. Thus, propofol affects its own pharmacokinetics, possibly by decreasing cardiac output and liver blood flow. A similar effect has also been shown with concomitant use of opioids, such as alfentanil and sufentanil.
Pharmacodynamic synergism has also been shown between propofol and opioids, such that the higher the opioid plasma concentration, the lower the plasma propofol concentration required for the same effect. It is also known that optimal propofol concentration is dependent on the opioid chosen and the length of infusion duration. Thus, the longer the context-sensitive half-life of the opioid, the more the opioid delays recovery.
In practice, this is seen when comparing fentanyl (long context-sensitive t 1/2 ) and remifentanil (short context-sensitive t 1/2 ). The pharmacodynamic variability observed between patients with respect to requirements for different levels of stimuli is 300-400%. This far exceeds the pharmacokinetic variability of 15-20%.
Remifentanil
Remifentanil is a µ-opioid receptor agonist that is metabolised by non-specific esterases throughout the body. Its metabolism is not affected by genetics, hepatic failure, renal failure or age. The context-sensitive t 1/2 is only 3-5 min, regardless of duration of dosing.
Remifentanil exhibits the same pharmacodynamic profile as other opioids, although it has a more rapid onset and offset. ) may cause chest wall rigidity and that alternative analgesia is established before the remifentanil infusion is switched off.
Under current investigation are TCI-remifentanil infusion systems with the potential for being patient-controlled to allow smoother transition into the postoperative period.
Neuromuscular blocking agents
The use of neuromuscular blockers in conjunction with TIVA is currently varied, depending on the anaesthetist and the surgery involved. It is not unusual to give a neuromuscular blocker only to facilitate intubation, especially when using remifentanil as the analgesic. In this situation, remifentanil allows toleration of the endotracheal tube, ventilation and surgery. The risk of awareness is diminished as the neuromuscular blocker is allowed to wear off. Neuromuscular blockers can be administered by bolus dosing, closed-loop systems and TCI systems. Currently, TCI systems are being investigated using pharmacokinetic and pharmacodynamic variables. Although these TCI systems work reasonably well, it can be demonstrated that the level of measured neuromuscular block is often different to the predicated value. This is due to pharmacokinetic factors such as age, renal or liver disease which can delay elimination by reducing clearance or increasing the apparent volume of distribution. Although their response may be more variable than other drugs, neuromuscular blockers have the advantage that their effect can be measured directly.
Equipment

Infusion pumps
The sophistication of syringe infusion pumps has developed rapidly. It is not so long ago that syringe pumps were simple, slow devices with limited functions and no protection against siphoning. Now, it may be said that they have developed to such an extent that they have become over-complicated and require extensive study themselves to ensure safe operation.
Important functions include:
• Bolus -gives the ability to increase quickly the plasma concentration
• Flow rate -the pump should be able to function accurately at flow rates from as little as 0.1 ml h -1 up to 1200 ml h -1
• Alarms -indicator of correct positioning of the syringe, high pressure within the system and stopping of the syringe
• Battery -indication of duration of battery
• Tight syringe fitting -the syringe plunger must fit securely in the clamp and not move without the pump running
Problems with infusion pumps
When a 50 ml syringe with a loose hanging infusion line is placed 125 cm above the ground it will empty in a few minutes. This is termed siphoning. If connected to a patient this could be disastrous. The risks can be minimized by using a securely fitting horizontal syringe and never placing the syringe high up. Backlash refers to the problem of delay after switching on the pump before any fluid leaves the syringe. It is prevented by purging the line. In addition, fluid may flow back into the syringe but this will not occur if the syringe is well secured in the pump. Accidental injection of air can occur and air within the syringe may delay the occlusion alarm because of its compressibility. Dead space of the infusion set is a frequent cause of interrupted drug flow, especially when it is connected to a drip. Therefore, the following are recommended:
• Avoid high concentration of drugs that run at low speeds 
Awareness
The prevention of awareness requires adequate depth of anaesthesia. The monitoring of the depth of anaesthesia is undergoing intense current interest and investigation presently. However, depth of anaesthesia is still commonly judged clinically by the observation of autonomic reflexes and patient movement, with all its limitations.
Comparison of the incidence of awareness with TIVA and volatile techniques remains controversial. With inhalational anaesthesia, end-tidal agent monitoring gives a good target during a procedure, but no such target exists with TIVA. Therefore, a good understanding of the pharmacokinetic and pharmacodynamic principles underlying the technique is important, and this, combined with targeting plasma and effect-site drug concentrations, form the basis of the current technique.
